Patient scheduling for gonadotrophin-releasing hormone antagonist protocols. - Wikidata - awgldk - TriplyDB

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

http://www.wikidata.org/entity/Q34591678

about

Use of oral contraceptives in infertile patients: A descriptive review.Weekend-free scheduled IVF/ICSI procedures and single embryo transfer do not reduce live-birth rates in a general infertile population.

P2860

Q36668521-867736CF-7704-4863-82CF-0F5043764495 Q47757356-C13F3DA3-4ACF-448F-B3FE-E51E22BDC999

P2860

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

http://www.wikidata.org/entity/Q34591678

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@en

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@nl

type

label

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@en

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@nl

prefLabel

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@en

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@nl

P1433

Q34591678-47C20F1F-167E-4166-9E28-CF056488EAF9

P1476

Q34591678-7C56CE01-0D06-416C-BFDF-B0450E28B4F8

P2860

Q34591678-148A5DF5-E152-451E-BF44-85C489A919BF

Q34591678-2572A5B6-0C59-455E-B4BE-39405E6AE4CE

Q34591678-35201D14-C39F-461E-9D71-E431F668EE1C

Q34591678-4A80E9EF-2113-4356-B1A8-5BF4AE523E0D

Q34591678-693622C6-43B3-4E0D-8960-3F2B0BA942BE

Q34591678-853B9096-6FC5-488D-8806-50673CB1FDCC

Q34591678-A5F2B31F-330D-4690-B4BF-8E385D08AC4D

Q34591678-ACC960EB-02B1-427C-BA68-AD65F0EE8DD5

Q34591678-D9E08047-B473-4EFE-A945-E00F4AD88E02

Q34591678-DA699B4E-88E9-414C-AD58-3E154A716B65

P304

Q34591678-58426434-B1B6-4D0F-89AB-A99318D67DB6

P31

Q34591678-1D034F5F-730E-43E3-9BF4-96F508002669

P356

Q34591678-7B11A88B-0178-4267-9FAA-F5204318ECBA

P433

Q34591678-D62D9196-D7D8-4767-A485-DF4205F45628

P478

Q34591678-72546058-FFB7-445E-AA36-E73020732535

P50

Q34591678-FDA83A21-2184-4C27-862A-705B04AFF60A

P577

Q34591678-CF0B9C5F-78BD-4E1A-A8A2-2704E2D6CCAB

P698

Q34591678-E0DB36D5-9187-44E0-98E7-D2FB783EF7FE

P356

1464727992000199801

P1433

Human Fertility

P1476

Patient scheduling for gonadotrophin-releasing hormone antagonist protocols.

@en

P2860

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.

Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.

Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial.

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.

Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran

Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial.

Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates.

Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization.

Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.

A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.

P304

G29-32; discussion G32-3, G41-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1464727992000199801

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11939158

http://www.w3.org/2001/XMLSchema#string